LARA (Launch Analog Recommendation Agent) is an AI-enabled tool to identify analog drugs to plan and benchmark launch access and performance
Analyzing analog drugs is a critical element of understanding market landscape, setting expectations and developing launch benchmarks.
But the analog selection is often rushed and handled sub-optimally due to the following challenges:
Absence of a single comprehensive repository of drugs which captures all the key criteria and characteristics
Critical drug and market characteristics are only available in an unstructured form need significant secondary research
Lack of a defined workflow and process for analog selection
LARA has been designed to make analog selection a fully-informed, efficient and streamlined exercise.
Key Features
Comprehensive drug repository with key absolute and relative characteristics
Streamlined agentic analog selection workflow
AI chatbot to enable to a conversational selection process
Dual mode operation: Guided suggestions-driven process vs. Fully AI-driven recommendations
Structured output formats (analog profiles, selection summary & rationale)
LARA leverages LLM to both curate/structure the drug repository and to power the agentic analog selection workflow
Conversational AI
& Dual Modality
- • AI chatbot for conversational querying and analog selection
- • Parallel templated user input interface (in addition to NL query)
- • UI designed for iterative and incremental selection process
- • Structured exportable outputs with the flexibility to reshape the output
Agentic RAG
Architecture
- • Multi-agent architecture: Query router, retrieval and summarization agents
- • Reduced/structured data + summarized unstructured information to retain context
- • Query builder tool for simple queries and drug look-ups
- • Pre-defined deterministic workflow to reduce agent ramble
Comprehensive Drug
Repository
- • Structured data from OpenFDA, Orange/Purple Book, Rx Norm, NDC Directory.
- • LLM based curation and structuring of the FDA labels
- • Longitudinal event tracking based on regulatory press releases and FDA documents
- • Normalized drug pricing; Derivative drug and market characteristics